ORIGINAL PAPER

Expedient one-pot three-component catalyst-free access to 5,6-dihydropyrimidin-4(*3H*)-one derivatives

Mehdi Ghandi · Maryam Jahangir Vazifeh

Received: 25 August 2014 / Accepted: 8 December 2014 © Iranian Chemical Society 2014

Abstract The synthesis of novel 5,6-dihydropyrimidin-4(3H)-one derivatives was accomplished in good yields via one-pot three-component condensation of Meldrum's acid, aldehydes and benzamidine in EtOH. Short reaction time, mild reaction condition, use of simple experimental procedure and prompt isolation of the products are some advantages of this protocol.

Keywords 5,6-Dihydropyrimidin-4(3H)-one · Benzamidine · Meldrum's acid · Three-component reaction

Introduction

The so-called multicomponent reactions (MCRs) are onepot processes in which at least three or more different simple substrates react for the preparation of target materials [1–7]. These reactions have gained much attention during the past years and frequently occur not through a singlestep procedure, but rather by several sequential steps or multicomponent cascade or domino reactions [8–13]. Simplicity, greater efficiency and atom economy with generation of molecular complexity and diversity in one-pot transformation are some of the advantages of these reactions.

The six-membered pyrimidines, abundantly widespread among natural bases [14–16], are an important class of heterocycles to medicinal chemistry due to their biological activities. These compounds have been reported as antitumor [17–20], interferon inducer [21–23], antiviral [24], anti-hypertensive [25, 26], hypoglycemic [27],

M. Ghandi (🖂) · M. J. Vazifeh

School of Chemistry, College of Science, University of Tehran, P.O. Box 14155 6455, Tehran, Iran e-mail: ghandi@khayam.ut.ac.ir anticonvulsant [28], antinociceptive [29, 30], anti-amoebic [31] and anti-inflammatory [32] agents.

As an important subclass of pyrimidine, the dihydropyrimidine and their derivatives are known as calcium channel modulators [33], mitotic kinesine inhibitors [34], adrenergic receptor antagonists [35], antibacterial [36], and antiviral agents [37].

Pyrimidine or pyrimidinone derivatives have traditionally been synthesized via condensation of a Michael acceptor with a uronium-containing molecule such as urea [38], thiourea [39], amidines [40], guanidines [41] or their derivatives. Due to the rather slow rates, 1 to 2 days are needed for the reactions to be completed. Therefore, different catalysts including BF₃.OEt₂ [42], LaCl₃.H₂O [43], InBr₃ [44], HY [45], amberlyst-15 or Nafion-H [46], montmorillonite-KSF [47], MCM-41-R-SO₃H [48], MCM-41 supported FeCl₃ [49] and amino-functionalized MCM-41 [50] have been used for these reactions. In addition, microwave radiation has also been used to accelerate reaction rates [40].

In continuation of our own interest in MCRs [51-54], herein we report an expedient one-pot three-component access to 5,6-dihydropyrimidin-4(3*H*)-one derivatives via condensation of Meldrum's acid, aldehydes and benzamidine in EtOH.

Experimental

General information

All commercially available chemicals and reagents were purchased from Merck Chemical Company and used without further purification. Melting points were determined with an Electrothermal model 9100 apparatus and are uncorrected. IR spectra were recorded on a Shimadzu 4300 spectrophotometer, in cm⁻¹. ¹H and ¹³C NMR spectra were recorded on a Bruker DRX-500-AVANCE spectrometer at 300 (¹H) and 75 MHz (¹³C) using CDCl₃ as solvent and with the residual solvent signal as internal reference (CDCl₃ 7.24 and 77.0 ppm). Mass spectra of the products were obtained with an HP (Agilent technologies) 5937 Mass Selective Detector. Elemental analyses were carried out by a CHN-Rapid Heraeus elemental analyzer (Wellesley, MA, USA).

General procedure for the preparation of **2a**–**n**

A mixture containing benzamidine hydrochloride (0.210 g, 1.2 mmol), triethylamine (0.101 g, 1.0 mmol), aldehydes **1a–n** (1.0 mmol) and Meldrum's acid (0.144 g, 1.0 mmol) in EtOH (3 mL) was stirred at reflux for 1 h. After completion as indicated by TLC, the solid was filtered and washed with EtOH to afford **2a–n**.

6-Butyl-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (2a) White solid, mp: 105–107 °C, yield: 0.168 g (73 %). IR (KBr) (ν_{max} , cm⁻¹): 3,288 (NH), 1,692 (C = O), 1,642 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H}$ = 0.95 (t, J = 7.0 Hz, 3H, CH₃CH₂), 1.36–1.86 (m, 6H, CH₂CH₂CH₂), 2.31(dd, J = 16.4, 11.2 Hz, 1H, CHCO), 2.60 (dd, J = 16.4, 5.2 Hz, 1H, CHCO), 3.70–3.80 (m, 1H, CHN), 7.42–7.52 (m, 3H, Ar), 7.79 (d, J = 6.3 Hz, 2H, Ar), 8.67 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C}$ = 14.0, 22.6, 28.1, 35.0, 35.5, 54.7, 126.5, 128.8, 131.1, 133.4, 151.5, 171.7 (C = O); EI-MS: m/z (%): 230 (21, M⁺), 215 (1.5), 201 (4), 173 (100), 159 (9), 104 (59), 77 (28); Anal. Calcd for C₁₄H₁₈N₂O (230.14): C 73.01, H 7.88, N 12.16 %. Found: C 72.59, H 8.20, N 11.77 %.

6-Phenethyl-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (2b) White solid, mp: 144–146 °C, yield: 0.222 g (80 %). IR (KBr) (ν_{max} , cm⁻¹): 3,253 (NH), 1,692 (C = O), 1,639 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H}$ = 1.88–2.00 (m, 1H, CHCHN), 2.04–2.16 (m, 1H, CHCHN), 2.35(dd, J = 16.4, 11.8 Hz, 1H, CHCO), 2.60 (dd, J = 16.5, 5.1 Hz, 1H, CHCO), 2.85–3.02 (m, 2H, CH₂Ph), 3.71-3.81 (m, 1H, CHN), 7.19–7.34 (m, 5H, Ar), 7.44-7.55(m, 3H, Ar), 7.82 (d, J = 6.7 Hz, 2H, Ar), 8.55 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C}$ = 32.2, 35.2, 37.4, 53.8, 125.9, 126.5, 128.4, 128.6, 128.9, 131.3, 133.3, 141.7, 150.5, 171.3 (CO); EI-MS: m/z (%): 278 (27, M⁺), 249 (4), 174 (100), 145 (26), 104 (43), 91 (17), 77 (21); Anal. Calcd for C₁₈H₁₈N₂O (278.14): C 77.67, H 6.52, N 10.06 %. Found: C 77.46, H 6.23, N 10.16 %.

6-(2,4-Dichlorophenyl)-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (**2c**) White solid, mp: 218–220 °C, yield: 0.217 g (68 %). IR (KBr) (ν_{max} , cm⁻¹): 3,246 (NH), 1,694 (C = O), 1,635 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.36$ (dd, J = 16.5, 13.6 Hz, 1H, CHCO), 3.01 (dd, J = 16.6, 5.0 Hz, 1H, CHCO), 5.28 (dd, J = 13.6, 5.0 Hz, 1H, CHN), 7.31 (dd, J = 8.4, 2.0 Hz, 1H, Ar), 7.42 (d, J = 2.0 Hz, 1H, Ar), 7.47–7.58 (m, 3H, Ar), 7.63 (d, J = 8.4 Hz, 1H, Ar), 7.87 (m, 2H, Ar), 8.80 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 35.8$, 55.7, 126.5, 127.7, 129.0, 129.2, 131.7, 131.9, 132.9, 133.7, 138.7, 152.1, 170.2 (CO); EI-MS: m/z (%): 322(20, M⁺, 2[³⁷Cl], 320 (77, M⁺, [³⁷Cl], [³⁵Cl]), 318 (84, M⁺, 2[³⁵Cl]), 291 (12), 283 (56), 267 (12), 226 (9), 173 (22), 104(100), 91(17), 77 (63 %); Anal. Calcd for C₁₆H₁₂C₁₂N₂O: C, 60.21; H, 3.79; N, 8.78. Found: C, 59.93; H, 3.61; N, 8.81.

2, 6-Diphenyl-5, 6-dihydropyrimidin-4(3H)-one (2d) White solid, mp: 185–187 °C, yield: 0.175 g (70%). IR (KBr) (ν_{max} , cm⁻¹): 3,239 (NH), 1,691 (C = O), 1,637 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H}$ = 2.61 (dd, J = 16.5, 12.4 Hz, 1H, CHCO), 2.88 (dd, J = 16.5, 5.4 Hz, 1H, CHCO), 4.98 (dd, J = 12.4, 5.3 Hz, 1H, CHN), 7.29-7.34 (m, 1H, Ar), 7.39 (t, J = 7.4 Hz, 2H, Ar), 7.46-7.56 (m, 5H, Ar), 7.90 (d, J = 6.8 Hz, 2H, Ar), 9.13 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C}$ = 37.5, 58.3, 126.6, 126.7, 127.4, 128.7, 128.8, 131.4, 133.2, 142.1, 151.4, 171.2 (CO); EI-MS: m/z (%): 250 (100, M⁺), 221(22), 193 (9), 173 (5), 147 (1.6), 104 (61), 77 (16); Anal. Calcd for C₁₆H₁₄N₂O (250.11): C 76.78, H 5.64, N 11.19 %. Found: C 76.36, H 5.23, N, 11.14 %.

6-(4-Bromophenyl)-2-phenyl-5, 6-dihydropyrimidin-4(3H)-one (2e) White solid, mp: 210–212 °C, yield: 0.171 g (52 %). IR (KBr) (ν_{max} , cm⁻¹): 3,250 (NH), 1,694 (C = O), 1,633 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.56$ (dd, J = 16.5, 12.8 Hz, 1H, CHCO), 2.86 (dd, J = 16.5, 5.2 Hz, 1H, CHCO), 4.93 (dd, J = 12.8, 5.2 Hz, 1H, CHN), 7.35 (d, J = 8.4 Hz, 2H, Ar), 7.46–7.57 (m, 5H, Ar), 7.85(d, J = 7.2 Hz, 2H, Ar), 8.47 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.4$, 57.8, 121.3, 126.5, 128.3, 128.9, 131.6, 131.8, 133.0, 141.2, 151.5, 170.2 (CO); EI-MS: *m/z* (%): 330 (70, M⁺ [⁸¹Br]), 328 (49, M⁺ [⁷⁹Br]), 299 (12), 273 (4), 249 (29), 104 (100), 77 (51); Anal. Calcd for C₁₆H₁₃BrN₂O (328.02): C 58.38, H 3.98, N 8.51 %. Found: C 58.46, H 3.93, N 8.59 %.

6-(4-Chlorophenyl)-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (**2**f) White solid, mp: 195–197 °C, yield: 0.25 g (88 %). IR (KBr) (ν_{max} , cm⁻¹): 3,230 (NH), 1,696 (C = O), 1,633 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.56$ (dd, J = 16.5, 12.8 Hz, 1H, CHCO), 2.86 (dd, J = 16.5, 5.2 Hz, 1H, CHCO), 4.95 (dd, J = 12.7, 5.2 Hz, 1H, CHN), 7.35-7.43 (m, 4H, Ar), 7.46-7.56 (m, 3H, Ar), 7.85(d, J = 6.8 Hz, 2H, Ar), 8.47 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.4$, 57.8, 126.5, 128.0, 128.8, 128.9, 131.6, 133.0, 133.2, 140.7, 151.5, 170.2 (CO); EI-MS: m/z (%): 286 (47, M⁺ [³⁷Cl]), 284 (100, M⁺ [³⁵Cl]), 255 (22), 227 (7), 138 (21), 104 (80), 77 (34); Anal. Calcd for C₁₆H₁₃ClN₂O (284.07): C 67.49, H 4.60, N 9.84 %. Found: C 67.48, H 4.49, N 9.94 %.

2-Phenyl-6-(*p*-tolyl)-5,6-dihydropyrimidin-4(3H)-one (2g) White solid, mp: 179–18 °C, yield: 0.14 g (53 %). IR (KBr) (ν_{max} cm⁻¹): 3,255 (NH), 1,692 (CO), 1,642 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.36$ (s, 3H, Me), 2.61 (dd, J = 16.5, 12.2 Hz, 1H, CHCO), 2.86 (dd, J = 16.5, 5.4 Hz, 1H, CHCO), 4.96 (dd, J = 12.1, 5.4 Hz, 1H, CHN), 7.19 (d, J = 7.9 Hz, 2H, Ar), 7.34 (d, J = 7.9 Hz, 2H, Ar), 7.45-7.53 (m, 3H, Ar), 7.87(d, J = 7.5 Hz, 2H, Ar), 8.69 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 21.1$, 37.5, 58.1, 126.4, 126.6, 128.8, 129.4, 131.4, 133.2, 137.0, 139.1, 151.1, 170.9 (CO); EI-MS: *m/z* (%): 264 (100, M⁺), 235 (27), 173 (4), 145 (16), 119 (27), 104 (35), 77 (20); Anal. Calcd for C₁₇H₁₆N₂O (264.13): C 77.25, H 6.10, N 10.60 %. Found: C 76.81, H 6.04, N 10.60 %.

6-([1,1'-Biphenyl]-4-yl)-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (**2h**) White solid, mp: 252–254 °C, yield: 0.231 g (71 %). IR (KBr) (ν_{max} , cm⁻¹): 3,257 (NH), 1,690 (C = O), 1,638 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.67$ (dd, J = 16.5, 12.4 Hz, 1H, CHCO), 2.93 (dd, J = 16.5, 5.4 Hz, 1H, CHCO), 5.04 (dd, J = 12.4, 5.3 Hz, 1H, CHN), 7.33-7.38 (m, 1H, Ar), 7.42–7.64 (m, 11H, Ar), 7.88 (dd, J = 6.6, 1.6 Hz, 2H, Ar), 8.41 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.1$, 57.2, 126.3, 126.6, 126.7, 126.8, 126.9, 127.8, 128.4, 130.4, 133.1, 139.1, 140.0, 141.5, 152.2, 170.3 (CO); EI-MS: *m/z* (%): 326 (35, M⁺), 297 (16), 180 (43), 165 (15), 152 (78), 104 (100), 77 (80); Anal. Calcd for C₂₂H₁₈N₂O (326.14): C 80.96, H 5.56, N 8.58 %. Found: C 80.92, H 5.30, N 8.64 %.

6-(4-Methoxyphenyl)-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (**2i**) White solid, mp: 157–159 °C, yield: 0.205 g (73 %). IR (KBr) (ν_{max} , cm⁻¹): 3,200 (NH), 1,704 (C = O), 1,653 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.45$ (dd, J = 16.5, 12.2 Hz, 1H, CHCO), 2.98 (dd, J = 16.5, 5.9 Hz, 1H, CHCO), 3.87 (s, 3H, Me), 5.32 (dd, J = 12.1, 5.4 Hz, 1H, CHN), 6.92 (d, J = 8.2 Hz, 1H, Ar), 7.01 (t, J = 7.6, 1H, Ar), 7.25–7.32 (m, 1H, Ar), 7.45-7.58 (m, 4H, Ar), 7.93 (d, J = 5.7 Hz, 2H, Ar), 9.31 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 35.9$, 53.2, 55.3, 110.3, 126.7, 128.4, 128.8, 130.5, 131.2, 133.4, 151.6, 156.3, 171.9; EI-MS: *m*/*z* (%): 280 (100, M⁺), 265 (34), 251 (24), 173 (12), 134 (19), 104 (75), 77 (40); Anal. Calcd for C₁₇H₁₆N₂O₂ (280.12): C 72.84, H 5.75, N 9.99 %. Found: C 73.08, H 5.67, N 10.15 %. 6-(3-Hydroxy-4-methoxyphenyl)-2-phenyl-5,6-dihydropyrimidin-4(3H)-one (2j) White solid, mp: 178-180 °C, yield: 0.186 g (63 %). IR (KBr) (ν_{max} , cm⁻¹): 3,439 (OH), 3,259 (NH), 1,695 (C = O), 1,640 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.59$ (dd, J = 16.5, 12.1 Hz, 1H, CHCO), 2.84 (dd, J = 16.5, 5.4 Hz, 1H, CHCO), 3.89 (s, 3H, Me), 4.90 (dd, J = 12.0, 5.4 Hz, 1H, CHN), 5.72 (s, 1H, OH), 6.84 (d, J = 8.3 Hz, 1H, Ph), 6.91 (dd, J = 8.3, 1.8 Hz, 1H, Ph), 7.03 (d, J = 1.8 Hz, 1H, Ph), 7.44–7.55 (m, 3H, Ph), 7.86 (d, *J* = 6.8 Hz, 2H, Ph), 8.60 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.5$, 56.0, 57.8, 110.8, 113.0, 118.0, 126.6, 128.8, 131.4, 133.1, 135.4, 145.8, 145.9, 151.1, 170.8 (CO); EI-MS: *m/z* (%): 296 (100, M⁺), 267 (22), 240 (4) 177 (15), 150 (16), 104 (39), 77 (20); Anal. Calcd for C₁₇H₁₆N₂O₃ (296.12): C 68.91, H 5.44, N 9.45 %. Found: C 69.19, H 5.04; N 9.10 %.

2-Phenyl-6-(3,4,5-trimethoxyphenyl)-5,6-dihydropyrimidin-4(3H)-one (**2k**) Pale yellow solid, mp: 157–158 °C, yield: 0.16 g (47 %). IR (KBr) (ν_{max} , cm⁻¹): 3,265 (NH), 1,690 (C = O), 1,647 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.62$ (dd, J = 16.4, 13.2 Hz, 1H, CHCO), 2.86 (dd, J = 16.5, 5.1 Hz, 1H, CHCO), 3.85 (s, 3H, Me), 3.88 (s, 6H, Me), 4.88 (dd, J = 13.1, 5.0 Hz, 1H, CHN), 6.69 (s, 2H, Ar), 7.46–7.57 (m, 3H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ph), 8.69 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.7$, 56.2, 58.6, 60.8, 103.6, 126.6, 128.9, 131.5, 133.1, 137.2, 138.0, 151.3, 153.45, 170.8 (CO); EI-MS: m/z (%): 340 (100, M⁺), 325 (41), 311 (14), 297 (9), 221(14), 194 (12), 104 (57), 77 (21); Anal. Calcd for C₁₉H₂₀N₂O₄ (340.14): C 67.05, H 5.92, N 8.23 %. Found: C 66.85, H 5.65, N 8.48 %.

6-(2-Nitrophenyl)-2-phenyl-5, 6-dihydropyrimidin-4(3H)-one (2I) Pale yellow solid, mp: 182–184 °C, yield: 0.163 g (55 %). IR (KBr) (ν_{max} , cm⁻¹): 3,362 (NH), 1,699 (C = O), 1,654 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.52$ (dd, J = 16.2, 14.3 Hz, 1H, CHCO), 3.12 (dd, J = 16.5, 4.8 Hz, 1H, CHCO), 5.52 (dd, J = 13.9, 4.8 Hz, 1H, CHN), 7.45–7.55 (m, 4H, Ar), 7.67 (t, J = 7.6 Hz, 1H, Ar), 7.84 (d, J = 7.8 Hz, 1H, Ar), 7.89 (d, J = 7.7 Hz, 2H, Ar), 7.98 (d, J = 8.1 Hz, 1H, Ar), 9.65 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 36.8$, 55.3, 124.6, 126.7,



Scheme 1 Preparation of dihydropyrimidin-4(3*H*)-one derivatives 2a–n

Table 1 Isolated yields obtained for 2a-n

Entry	Aldehyde	product	Yield (%)
1	Me H O	Me NH O 2a	73
2	С О Ib	2b	80
3	Cl Cl H O Ic	$Cl \qquad Cl \qquad N \qquad O$	40
4	H O Id	N NH O 2d	70
5	Br H O Ie	Br N N N H O Ze	52
6	Cl H O If	Cl N NH O 2f	88
7	Me H O 1g	Me N N N N N N H O 2g	53

Table 1 continued



128.3, 128.9, 129.9, 131.6, 132.8, 133.8, 138.1, 148.2, 152.2, 170.9; EI-MS: *m/z* (%): 296 (4, M⁺+1), 278 (12), 247 (43), 220 (24), 147 (100), 104 (94), 77 (51); Anal. Calcd

for $C_{16}H_{13}N_3O_3$ (295.10): C 65.08, H 4.44, N 14.23 %. Found: C 64.75, H 4.20, N 14.24 %.



Scheme 2 Mechanistic rationalization for the formation of compound 2a-n

6-(3-Nitrophenyl)-2-phenyl-5, 6-dihydropyrimidin-4(3H)-one (**2m**) Pale yellow solid, mp: 196–198 °C, yield: 0.170 g (57 %). IR (KBr) (ν_{max} , cm⁻¹): 3,215 (NH), 1,691 (C = O), 1,641 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.59$ (dd, J = 16.2, 13.8 Hz, 1H, CHCO), 2.93 (dd, J = 16.5, 5.1 Hz, 1H, CHCO), 5.06 (dd, J = 13.8, 5.1 Hz, 1H, CHCO), 5.06 (dd, J = 13.8, 5.1 Hz, 1H, CHCO), 7.83 (d, J = 7.5 Hz, 1H, Ar), 7.91 (d, J = 7.2 Hz, 2H, Ar), 8.19 (d, J = 8.1 Hz, 1H, Ar), 8.41 (s, 1H, Ar), 8.98 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.3$, 57.7, 121.9, 122.5, 126.6, 129.0, 129.7, 131.8, 132.7, 132.8, 144.5, 148.6, 152.2, 170.2 (CO); EI-MS: m/z (%): 296 (76, M⁺+1), 278 (4), 248 (4), 220 (2), 173 (10), 104 (100), 77 (38); Anal. Calcd for C₁₆H₁₃N₃O₃ (295.10): C 65.08, H 4.44, N 14.23 %. Found: C 64.92, H 4.28, N 14.23 %.

6-(2-*Chlorophenyl*)-2-*phenyl*-5,6-*dihydropyrimidin-4(3H)-one* (**2n**) White solid, mp: 176–178 °C, yield: 0.154 (54 %). IR (KBr) (ν_{max} , cm⁻¹): 3,268 (NH), 1,695 (C = O), 1,638 (C = N); ¹H-NMR (300 MHZ, CDCl₃): $\delta_{\rm H} = 2.56$ (dd, J = 16.5, 13.1 Hz, 1H, CHCO), 2.85 (dd, J = 16.5, 5.2 Hz, 1H, CHCO), 4.92 (dd, J = 13.1, 5.2 Hz, 1H, CHN), 7.27–7.34 (m, 3H, Ar), 7.45–7.57 (m, 4H, Ar), 7.90 (d, J = 6.7 Hz, 2H, Ar), 9.27 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): $\delta_{\rm C} = 37.4$, 57.8, 124.8, 126.7, 126.9, 127.6, 128.9, 130.0, 131.6, 132.9, 134.6, 144.3, 151.9, 171.0 (CO); EI-MS: *m/z* (%): 286 (5, M⁺ [³⁷Cl]), 284 (100, M⁺, [³⁵Cl]), 255 (20), 249 (12), 227 (9), 138 (19), 104 (96), 77 (43); Anal. Calcd for C₁₆H₁₃CIN₂O (284.07): C 67.49, H 4.60, N 9.84 %. Found: C 67.37, H 4.30, N 9.85 %.

Results and discussion

Reaction of Meldrum's acid with benzamidine hydrochloride and benzaldehyde **1a-n** in EtOH in the presence of Et₃N at reflux over 1 h afforded 2a-n (Scheme 1; Table 1). The structures of products were deduced by elemental analysis, MS, IR, ¹H NMR, and ¹³C NMR spectroscopy. For example, the mass spectra of **2f** displayed the molecular ion peak at 284 for M^+ ([³⁵Cl]) and 286 for M^+ ([³⁷Cl]) consistent with the molecular structure. The IR spectrum of 2a displayed characteristic absorption bands at 3,220 and 1,696 cm^{-1} due to N–H and C = O stretching vibrations, respectively. The 1 H NMR spectrum of **2a** showed three doublet of doublets at δ 2.56 (J = 16.5, 12.8 Hz, 1H), 2.86 (J = 16.5, 5.2 Hz, 1H), 4.95 (J = 12.8, 5.2 Hz, 1H) and one singlet at δ 8.47 (1H) due to the CHC = O, CHC = O, CHN and NH protons, respectively. Moreover, the ¹³C NMR spectrum of 2a displayed 12 distinct signals including one appearing at δ 170.2 for C = O carbon, consistent with molecular structure.

As illustrated in Table 1, aliphatic or a range of electrondonating or electron-withdrawing substituted aromatic aldehydes are tolerated in these one-pot three-component reactions.

Although the precise mechanism is not known, a mechanistic postulate as shown in Scheme 2 may be invoked to rationalize the formation of **2a-n**. It is conceivable that the in situ generated Knoevenagel adducts I_1 undergoes Michael addition by the liberated free benzamidine, affording the intermediate I_2 . The β -ketoacid I_3 intermediate is subsequently generated via attack of the second benzamidine NH group to C = O of the I_2 with concomitant losing acetone. Upon thermal decarboxylation, it finally affords the products **2a-n**.

Conclusion

In conclusion, we have described a convenient route to novel 5,6-dihydropyrimidin-4(3H)-one derivatives from Meldrum's acid, aldehydes and benzamidine in EtOH. The 5,6-dihydropyrimidin-4(3H)-ones reported in this work broaden the scaffolds that are accessible through MCRs and seem to be of potential interest for drug discovery. The advantages of the present procedure are short reaction time, mild reaction condition, use of simple experimental procedure and prompt isolation of the products with generation of interesting heterocycles in one-pot transformation.

Acknowledgments The authors acknowledge the University of Tehran for financial support of this research.

References

- B. Liang, S. Kalidindi, J.A. Porco Jr, C.R.J. Stephenson, Org. Lett. 12, 572 (2010)
- 2. B. Ganem, Acc Chem Res 42, 463 (2009)
- 3. S.L. Cui, X.F. Lin, Y.G. Wang, Org Lett 8, 4517 (2006)
- J. Zhu, H. Bienamye, *Multicomponent reactions* (VCH, Weinheim, 2005)
- C. Simon, T. Constantieux, J. Rodriguez, Eur. J. Org. Chem. 4957 (2004)
- 6. M. Murakami, Angew Chem Int Ed 42, 718 (2003)
- A. Jacobi Von Vangelin, H. Neumann, D. Grdes, S. Klaus, D. Strübing, D. Beller, M Chem Eur J 9, 4286 (2003)
- K. Kriis, K. Ausmees, T. Pehk, M. Lopp, T. Kanger, Org Lett 12, 2230 (2010)
- 9. A. Dömling, Chem Rev 106, 17 (2006)
- 10. C. Hulme, V. Gore, Curr Med Chem 10, 51 (2003)
- V. Nair, C. Rajesh, A.U. Vinod, A.U. Bindu, A.R. Sreekanth, J.S. Mathen, L. Balagopal, Acc Chem Res 36, 899 (2003)
- 12. I. Ugi, B. Verner, A. Dmling, Molecules 8, 53 (2003)
- 13. J. Zhu, Eur. J. Org. Chem. 1133 (2003)
- H. Shao, S. Shi, D.W. Foley, F. Lam, A.Y. Abbas, X. Liu, S. Huang, X. Jiang, N. Baharin, P.M. Fischer, S. Wang, Eur J Med Chem 70, 447 (2013)
- O.N. Al-Safarjalani, X.J. Zhou, R.H. Rais, J. Shi, R.F. Schinazi, F.N. Naguib, M.H. El-Kouni, Cancer Chemother Pharmacol 55, 541 (2005)
- 16. D.J. Brown, The pyrimidines (Wiley, New York, 1994)
- M.M. Kandeel, L.W. Mohamed, M.K. Abdel Hamid, A.T. Negmeldin, Sci Pharm 80, 531 (2012)
- H.Y. He, J.N. Zhao, R. Jia, Y.L. Zhao, S.Y. Yang, L.T. Yu, L. Yang, Molecules 16, 10685 (2011)
- M. Scheringa, J.N. Ijzermans, J. Jeekel, R.L. Marquet, Cancer Immunol Immunother 32, 251 (1990)
- 20. D.A. Adv, Enzyme Regul 19, 335 (1981)
- J.V. dos Anjos, R.M. Srivastava, J.H. Costa-Silva, L. Scotti, M.T. Scotti, A.G. Wanderley, E.S. Leite, S.J. de Melo, F.J.B. Mendonça Jr, Molecules 17, 809 (2012)

- S.M. Vroegop, D.L. Chapman, D.E. Decker, L.A. Galinet, R.J. Brideau, K.A. Ready, C.J. Dunn, S.E. Buxser, Int J Immunopharmacol 21, 647 (1999)
- 23. Cancer Immunol Immunother, 32, 251 (1990)
- R. Saladino, U. Ciambecchini, G. Maga, P. Mastromarino, C. Conti, M.A. Botta, Bioorg Med Chem Lett. 10, 2143 (2002)
- O. Alam, S.A. Khan, N. Siddiqui, W. Ahsan, S.P. Verma, S.J. Gilani, Eur J Med Chem 45, 5113 (2010)
- A. Salimbeni, R. Canevotti, F. Paleari, D. Poma, S. Caliari, F. Fici, R. Cirillo, A.R. Renzetti, A. Subissi, L. Belvisi, G. Bravi, C. Scolastico, A. Giachetti, A J Med Chem 38, 4806 (1995)
- M. Yamaguchi, K. Wakasugi, R. Saito, Y. Adachi, Y. Yoshikawa, H. Sakurai, A.J. Katoh, Org Biochem 100, 260 (2006)
- D.C. White, T.D. Greenwood, A.L. Downey, J.R. Bloomquist, J.F. Wolfe, Bioorg Med Chem 12, 5711 (2004)
- A. Ranise, O. Bruno, F. Bondavalli, S. Schenone, M. D'Amico, M. Falciani, W. Filippelli, F. Rossi, Farmaco 49, 551 (1994)
- J.V. dos Anjos, R.M. Srivastava, J.H. Costa-Silva, L. Scotti, M.T. Scotti, A.G. Wanderley, E.S. Leite, S.J. Melo, Molecules 16, 809 (2012)
- A.R. Bhat, M. Arshad, E.J. Lee, S. Pokharel, I. Choi, F. Athar, Chem Biodivers 10, 2267 (2013)
- J.V. dos Anjos, F.J.B. Mendonça Jr, J.H. Costa-Silva, I.A. de Souza, S.J. Melo, Lat Am J Pharm 27, 343 (2008)
- R. Budriesi, A. Bisi, P. Ioan, A. Rampa, S. Gobbi, F. Belluti, L. Piazzi, P. Valenti, A. Chiarini, Bioorg Med Chem 13, 3423 (2005)
- H.Y. Kristal Kaan, V Ulaganathan, O. Rath, H. Prokopcová, D. Dallinger, C.O. Kappe, J. Med. Chem. 53, 5676 (2010)
- P.G. Nantermet, J.C. Barrowa, H.G. Selnick, C.F. Homnick, R.M. Freidinger, R.S.L. Chang, S.S. O'Malley, D.R. Reiss, T.P. Broten, R.W. Ransom, D.J. Pettibone, T. Olah, C. Forray, Bioorg Med Chem Lett 10, 1625 (2000)
- 36. N. Reshma, J.N. Harsha, I. Der. Pharma. Chemica. 6, 135 (2014)
- R. Surendra Kumar, A. Idhayadhulla, A. J. Abdul Nasser, J. Selvin, Eur. J. Med. Chem. 46, 804 (2011)
- 38. C.O. Kappe, Eur J Med Chem **35**, 1043 (2000)
- M.S. Mohamed, S.M. Awad, Y.M. Zohny, Z.M. Mohamed, Pharmacophore 3, 62 (2012)
- A.L. Xavier, A.M. Simas, E.P.S. Falcão, J.V. dos Anjos, Tetrahedron Lett 54, 3462 (2013)
- 41. S.S. Bahekar, D.B. Shinde, Acta Pharm **53**, 223 (2003)
- 42. E.H. Hu, D.R. Silder, U.H. Dolling, J Org Chem 63, 3454 (1998)
- J. Lu, Y. Bai, Z. Wang, B. Yang, H. Ma, Tetrahedron Lett 41, 9075 (2000)
- N.Y. Fu, Y.F. Yauan, Z. Cao, S.W. Wang, J.T. Wang, C. Pepple, Tetrahedron 58, 4801 (2002)
- V.R. Rani, N. Srinivas, M.R. Kishan, S.J. Kulkarni, K.V. Raghvan, Green Chem 3, 305 (2000)
- J.S. Reddy, B.V.S. Reddy, E.J. Reddy, T. Ramalingam, J. Chem. Res. 354 (2000)
- 47. H. Lin, J. Ding, X. Chen, Z. Zhang, Molecules 5, 1240 (2000)
- 48. G.H. Mahdavinia, H. Sepehrian, Chin Chem Lett **19**, 1435 (2008) 49. V.R. Choudhary, V.H. Tillu, V.S. Narkhede, H.B. Borate, R.D.
- Wakharkar, Catal Commun 4, 449 (2003)
 50. M. Mirza-Aghayan, T.B. Lashaki, M. Rahimifard, R. Boukherroub, A.A. Tarlania, J Iran Chem Soc 8, 280 (2011)
- 51. M. Ghandi, N. Zarezadeh, A. Taheri, Tetrahedron Lett 53, 3353 (2012)
- 52. M. Ghandi, N. Zarezadeh, A. Taheri, Tetrahedron Lett **52**, 1228 (2011)
- 53. M. Ghandi, N. Zarezadeh, A. Taheri, Tetrahedron 66, 8231 (2010)
- M. Ghandi, A. Tabatabaei Ghomi, M. Kubicki, J Org Chem 78, 2611 (2013)